Korro Bio, Inc. Financing Cash Flow
Korro Bio, Inc. (KRRO) reported Financing Cash Flow of $85.30 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-06
- Korro Bio, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was -$2.92M, a 58440.00% decline year-over-year.
- Korro Bio, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $88.21M, a 51186.05% increase year-over-year.
- Korro Bio, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $380.00K, a 59.23% decline year-over-year.
- Korro Bio, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $128.00K, a 82.42% decline year-over-year.
- Korro Bio, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $685.00K, a 99.01% decline from fiscal 2024.
- Korro Bio, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $69.36M, a 63.06% decline from fiscal 2023.
- Korro Bio, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $187.76M, a 1043016.67% increase from fiscal 2022.
- Korro Bio, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $18.00K, a 98.67% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 3 month as first filed | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 6 month as first filed | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 9 month as first filed | Net Cash Provided by (Used in) Financing Activities 12 month | Net Cash Provided by (Used in) Financing Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$2.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $85.30M 10-Q · filed 2026-08-06 | $85.67M derived: sum of 3 quarters · filed 2026-08-06 | $85.80M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $88.21M 10-Q · filed 2026-05-07 | $88.59M derived: sum of 2 quarters · filed 2026-05-07 | $88.72M derived: sum of 3 quarters · filed 2026-05-07 | $88.72M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $380.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $508.00K derived: sum of 2 quarters · filed 2026-03-12 | $513.00K derived: sum of 3 quarters · filed 2026-08-06 | $685.00K 10-K · filed 2026-03-12 | ||||
| 2025-09-30 | $128.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $133.00K derived: sum of 2 quarters · filed 2026-08-06 | $305.00K 10-Q · filed 2025-11-12 | $1.24M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $5.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $177.00K 10-Q · filed 2026-08-06 | $1.11M derived: sum of 3 quarters · filed 2026-08-06 | $1.84M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $172.00K 10-Q · filed 2026-05-07 | $1.10M derived: sum of 2 quarters · filed 2026-05-07 | $1.83M derived: sum of 3 quarters · filed 2026-05-07 | $69.39M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | $932.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $1.66M derived: sum of 2 quarters · filed 2026-03-12 | $69.22M derived: sum of 3 quarters · filed 2026-03-12 | $69.36M 10-K · filed 2026-03-12 | ||||
| 2024-09-30 | $728.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $68.28M derived: sum of 2 quarters · filed 2025-11-12 | $68.42M 10-Q · filed 2025-11-12 | $213.01M derived: sum of 4 quarters · filed 2025-11-12 | ||||
| 2024-06-30 | $67.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $67.69M 10-Q · filed 2025-08-12 | $212.28M derived: sum of 3 quarters · filed 2025-08-12 | $210.09M derived: sum of 4 quarters · filed 2025-08-12 | ||||
| 2024-03-31 | $139.00K 10-Q · filed 2025-05-07 | $144.73M derived: sum of 2 quarters · filed 2025-05-07 | $142.53M derived: sum of 3 quarters · filed 2025-05-07 | $142.50M derived: sum of 4 quarters · filed 2025-05-07 | ||||
| 2023-12-31 | $144.59M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $142.40M derived: sum of 2 quarters · filed 2025-03-18 | $142.36M derived: sum of 3 quarters · filed 2025-03-18 | $187.76M 10-K · filed 2025-03-18 | ||||
| 2023-09-30 | -$2.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$2.23M derived: sum of 2 quarters · filed 2024-11-12 | $43.17M 10-Q · filed 2024-11-12 | -$14.13M 10-Q · filed 2023-11-02 | $42.94M derived: sum of 4 quarters · filed 2024-11-12 | |||
| 2023-06-30 | -$36.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $45.37M 10-Q · filed 2024-08-13 | -$14.13M 10-Q · filed 2023-08-10 | $45.13M derived: sum of 3 quarters · filed 2024-08-13 | $45.18M derived: sum of 4 quarters · filed 2024-08-13 | |||
| 2023-03-31 | $45.40M 10-Q · filed 2024-05-14 | -$2.47M 10-Q · filed 2023-05-12 | $45.16M derived: sum of 2 quarters · filed 2024-05-14 | $45.22M derived: sum of 3 quarters · filed 2024-05-14 | $45.22M derived: sum of 4 quarters · filed 2024-05-14 | |||
| 2022-12-31 | -$238.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | -$182.00K derived: sum of 2 quarters · filed 2024-03-26 | -$182.00K derived: sum of 3 quarters · filed 2024-03-26 | $18.00K 10-K · filed 2024-03-26 | -$577.00K 10-K · filed 2023-03-10 | |||
| 2022-09-30 | $56.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $56.00K derived: sum of 2 quarters · filed 2023-11-02 | $256.00K 10-Q · filed 2023-11-02 | $365.00K derived: sum of 4 quarters · filed 2023-11-02 | ||||
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $200.00K 10-Q · filed 2023-08-10 | $309.00K derived: sum of 3 quarters · filed 2023-08-10 | $658.00K derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | $200.00K 10-Q · filed 2023-05-12 | $309.00K derived: sum of 2 quarters · filed 2023-05-12 | $658.00K derived: sum of 3 quarters · filed 2023-05-12 | $986.00K derived: sum of 4 quarters · filed 2023-05-12 | ||||
| 2021-12-31 | $109.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | $458.00K derived: sum of 2 quarters · filed 2023-03-10 | $786.00K derived: sum of 3 quarters · filed 2023-03-10 | $1.36M 10-K · filed 2023-03-10 | ||||
| 2021-09-30 | $349.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $677.00K derived: sum of 2 quarters · filed 2022-11-08 | $1.25M 10-Q · filed 2022-11-08 | $16.63M derived: sum of 4 quarters · filed 2022-11-08 | ||||
| 2021-06-30 | $328.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $900.00K 10-Q · filed 2022-08-09 | $16.28M derived: sum of 3 quarters · filed 2022-08-09 | $56.89M derived: sum of 4 quarters · filed 2022-08-09 | ||||
| 2021-03-31 | $572.00K 10-Q · filed 2022-05-04 | $15.96M derived: sum of 2 quarters · filed 2022-05-04 | $56.56M derived: sum of 3 quarters · filed 2022-05-04 | $56.95M derived: sum of 4 quarters · filed 2022-05-04 | ||||
| 2020-12-31 | $15.38M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $55.99M derived: sum of 2 quarters · filed 2022-03-15 | $56.38M derived: sum of 3 quarters · filed 2022-03-15 | $56.69M 10-K · filed 2022-03-15 | ||||
| 2020-09-30 | $40.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $41.00M derived: sum of 2 quarters · filed 2021-11-15 | $41.30M 10-Q · filed 2021-11-15 | $123.50M derived: sum of 4 quarters · filed 2021-11-15 | ||||
| 2020-06-30 | $391.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $700.00K 10-Q · filed 2021-08-12 | $82.90M derived: sum of 3 quarters · filed 2021-08-12 | $142.28M derived: sum of 4 quarters · filed 2021-08-12 | ||||
| 2020-03-31 | $309.00K 10-Q · filed 2021-05-13 | $82.51M derived: sum of 2 quarters · filed 2021-05-13 | $141.89M derived: sum of 3 quarters · filed 2021-05-13 | $141.98M derived: sum of 4 quarters · filed 2021-05-13 | ||||
| 2019-12-31 | $82.20M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $141.59M derived: sum of 2 quarters · filed 2021-03-29 | $141.67M derived: sum of 3 quarters · filed 2021-03-29 | $142.01M 10-K · filed 2021-03-29 | ||||
| 2019-09-30 | $59.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | $59.48M derived: sum of 2 quarters · filed 2020-11-16 | $59.82M 10-Q · filed 2020-11-16 | $94.69M derived: sum of 4 quarters · filed 2020-11-16 | ||||
| 2019-06-30 | $88.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | $430.00K 10-Q · filed 2020-08-12 | $35.30M derived: sum of 3 quarters · filed 2020-08-12 | |||||
| 2019-03-31 | $342.00K 10-Q · filed 2020-05-14 | $35.21M derived: sum of 2 quarters · filed 2020-05-14 | ||||||
| 2018-12-31 | $34.87M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | $41.71M 10-K · filed 2020-03-26 | ||||||
| 2018-09-30 | $6.84M 10-Q · filed 2019-11-18 | |||||||
| 2017-12-31 | $27.98M 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |